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BACKGROUND: Hopelessness is associated with mor-
tality in patients with cardiac disease even after ac-
counting for severity of depression. We sought to
determine whether a polymorphism in the promoter
region of the serotonin transporter gene (5-HTTLPR) is
associated with increased hopelessness, and whether
this effect is modified by sex, age, antidepressant use or
depression in patients with coronary heart disease.
METHODS: We conducted a cross-sectional study of
870 patients with stable coronary heart disease. Our
primary outcomes were hopelessness score (range 0-8)
and hopeless category (low, moderate and high) as
measured by the Everson hopelessness scale. Analysis
of covariance and ordinal logistic regression were used
to examine the independent association of genotype
with hopelessness.
RESULTS: Compared to patients with l/l genotype,
adjusted odds of a higher hopeless category increased
by 35% for the l/s genotype and 80% for s/s genotype
(p-value for trend=0.004). Analysis of covariance dem-
onstrated that the effect of 5-HTTLPR genotype on
hopelessness was modified by sex (.04), but not by
racial group (p=0.63). Among men, odds of higher
hopeless category increased by 40% for the l/s genotype
and by 2.3-fold for s/s genotype (p-value p<0.001),
compared to no effect in the smaller female sample (p=
0.42). Results stratified by race demonstrated a similar
dose-response effect of the s allele on hopelessness
across racial groups.
CONCLUSIONS: We found that the 5-HTTLPR is inde-
pendently associated with hopelessness among men
with cardiovascular disease.
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BACKGROUND
Hopelessness, defined as a sense of futility and negative future
orientation, is associated with worse medical outcomes
1–4.
Among patients with cardiovascular disease, hopelessness
predicts incident myocardial infarction and cardiovascular
mortality
2. Although it is widely accepted that hopelessness is a
typical feature of depression
5, there is substantial evidence for
the functional independence of hopelessness and depression
6,7.
Furthermore, hopelessness is more common than depression
1,2,
and the strength of the association between hopelessness and
adverse cardiovascular outcomes has been found to be distinct
from and stronger than that associated with depression
1,8.
Several factors impact patients’ sense of hope, including
socioeconomic status, family support, severity of illness and co-
morbidities. Genetic predisposition is also likely to play a role,
and in recent years, there has been increased interest in
investigating the genetic component of both psychiatric dis-
orders and healthy psychiatric characteristics. A breakthrough
in this research has been the description of the short (s) allele of
5-HTTLPR (serotonin transporter length polymorphic region), a
common functional polymorphism in the promoter region of the
serotonin transporter gene (SLC6A4). Compared to the longer (l)
allele variant, the s allele results in less efficient transcription of
the serotonin transporter gene
9,10, increased cardiac reactivi-
ty
11, and it has been associated with less resilience to the
depressogenic effects of adverse life events
12,p o o r e rr e s p o n s et o
selective serotonin reuptake inhibitor (SSRI) antidepressant
therapy
13, and with clinical and subclinical depression
14–23.
Previously, Otte and colleagues found that the short allele of
5-HTTLPR predicted major depressive disorder, higher perceived
stress, and norepinephrine secretion in the Heart and Soul
Study
22. However, the association between the 5-HTTLPR
polymorphism and depression has more recently been called
into question, with a meta-analysis demonstrating no evidence
of interaction between the s allele and stressful life events on
development of depression
24. Given the heterogeneity of depres-
sion, one possible explanation for these discordant results is
that 5-HTTLPR may be associated with some aspects of
depression, and not with others. For example, Gonda and
colleagues
15 recently described an association between the s
allele of 5-HTTLPR and several elements of “neuroticism-related
traits” including anxiety, depression, hopelessness, guilt, hos-
tility, aggression, and somatization in a group of healthy women.
Thus, the genetic basis of the components of sub-clinical
Findings were presented at the Annual Society of General Internal
Medicine meeting on May 14, 2009 in Miami, Florida.
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1030depression may offer insights into this controversy. Further,
emerging data has suggested that serotonergic function modu-
lated by 5-HTTLPR may vary according to age and sex, where
patients over 25 years of age and men with s allele carriage have
been found to be at increased risk of SSRI non-response
compared to younger patients and women
25,26. Sex differences
in 5-HTTLPR moderation of response to SSRI antidepressants,
tryptophan depletion and stressful life events have also been
observed
25,27,28.
No study has evaluated whether the 5-HTTLPR s allele is
associated with increased susceptibility to hopelessness among
patients with chronic illness. We sought to determine whether
presence of the s allele is associated with greater propensity to
hopelessness in patients with chronic cardiovascular disease
independent of depression. The following were our objectives: 1)
todeterminetheindependentassociationbetweenthe5-HTTLPR
s allele and hopelessness and 2) to determine whether the effect
between 5-HTTLPR s allele and hopelessness was moderated by
race, sex, social support or presence of depression.
METHODS
Sites and subjects. We studied patients enrolled in the Heart
and Soul Study, details of which have been published
previously
29. Briefly, participants were prospectively enrolled
at 2 Department of Veterans Affairs (VA) medical centers (San
Francisco VA Medical Center and VA Palo Alto Health Care
System), one university center (University of California, San
Francisco) and nine public health clinics in the Community
Health Network of San Francisco. Eligible patients had at least
one of the following: a history of myocardial infarction,
angiographic evidence of ≥50% stenosis in one or more
coronary vessels, history of coronary revascularization or prior
evidence of exercise-induced ischemia by treadmill or nuclear
testing. All study participants completed a self-administered
questionnaire during a daylong study appointment. The study
was approved by the appropriate institutional review boards
and written informed consent was obtained from all
participants after complete description of the study.
This analysis includes 870 (85%) of the 1,024 participants
in the Heart and Soul Study. Of the 154 patients excluded, five
did not complete the hopelessness survey, one did not provide
information on race, 116 patients did not have genotyping, and
thirty-two patients had at least one rare 5-HTTLPR variant
(generally 18 or 20 repeats), the transcriptional efficiency of
which is unknown
30.
5-HTTLPR Genotyping
Sample collection, DNA extraction and storage, amplification
and genotyping procedures are described elsewhere
22. Result-
ing genotypes of 5-HTTLPR were described as l/l, l/s or s/s.
Laboratory personnel were blind to hopelessness scores.
Hopelessness
We assessed current hopelessness using the Everson two-item
hopelessness scale, a previously validated instrument
2. The
scale contains the following questions: 1) “I feel that it is
impossible to reach the goals I would like to strive for”, and 2)
“The future seems to me to be hopeless, and I can’t believe that
things are changing for the better”. Responses are scored as 0
(absolutely disagree), 1 (somewhat disagree), 2 (cannot say), 3
(somewhat agree), and 4 (absolutely agree), with a summary
score ranging from 0 to 8 (higher scores indicate greater
hopelessness). We categorized hopelessness as defined by
Everson et al.
2: Low (0-2), moderate (3-5), high (6-8).
Other Patient Characteristics and Covariates
Self-reported age, race, gender, marital status, income, educa-
tion, smoking and alcohol use were determined by self-
administered questionnaire. Race categories included on the
survey were 1) Hispanic, Latino, or Latin American; 2) Asian or
Pacific Islander; 3) Black or African American; 4) White or
Caucasian; 5) Another group not listed. We used the terms:
“Latino”, “Asian”, “African American”, “White” and “Other” to
describe the groups throughout the manuscript. We measured
height and weight and calculated body mass index. Partici-
pants were instructed to bring all medication to their appoint-
ment where study personnel recorded and categorized
medications using Epocrates Rx (San Mateo, California). We
measured depressive symptoms using the 9-item Patient
Health Questionnaire (PHQ-9) score
31,32, a self-report instru-
ment that has excellent validity for diagnosing depression in
patients with coronary disease
33, and which also predicts
adverse cardiovascular outcomes
34. We also ascertained the
presence of a current major depressive disorder using the
Computerized Diagnostic Interview Schedule
35 for DSM-IV
(CDIS-IV). Participants with a major depressive episode in the
past month were informed of this diagnosis, instructed to
discuss their symptoms with their primary care provider, and
provided a list of local resources available for treatment. We
measured social support using a single question with a
dichotomous response, “Do you have as much contact as you
would like with someone you feel close to, someone in whom
you can trust and confide?”
Statistical Analysis
The primary goal of this study was to investigate the indepen-
dent association between the s allele variant of the 5-HTTLPR
polymorphism and hopelessness. We considered autosomal
dominant, autosomal recessive and dose-response effects of the
s allele in our analysis. Genotypes were classified separately
accordingtolevelsoftranscriptional efficiency
9,16,wherel/lwas
coded as 0, s/l was coded as 1, and s/s was coded as 2. In our
analysis, the dose response model best characterized the
association between 5-HTTLPR genotype and hopelessness.
Differences in characteristics between participants by 5-
HTTLPR genotype (l/l, l/s and s/s) were determined using chi
square (for dichotomous variables) or analysis of variance (for
continuous variables). We used two models to evaluate the
association between 5-HTTLPR genotype and measured hope-
lessness: In the first, we used analysis of covariance to
calculate mean hopelessness scores according to genotype.
This model was used for its increased sensitivity to test for
effect modifying and confounding variables to establish a final
adjusted model. We considered the effects of interactions
between 5-HTTLPR and potential effect modifiers including
race, depressive symptoms, major depressive disorder, antide-
pressant use, social support, sex and age. Then, we used a
proportional odds final adjusted model to estimate the inde-
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less category (low, moderate, high). We verified the proportional
odds assumption that the association between 5-HTTLPR
genotype and each possible dichotomous outcome variable
that could be constructed from the ordinal hopelessness
categories (high vs. low-moderate and low vs. moderate-high)
can be described by only two odds-ratios, one for l/s and the
other for s/s.
Covariates. In order to avoid population stratification
36–38,w e
adjusted for self-reported race in all pooled and composite
“non-white” analyses. In our final adjusted model, we also
included as covariates age, antidepressant use and depressive
symptoms (PHQ-9 score). These were chosen on the basis of
clinical validity and prior literature demonstrating an
association between age, depressive symptoms and response
to antidepressants with 5-HTTLPR
39,40. We tested our final
model using two sensitivity analyses: 1) We excluded patients
with CDIS IV current depressive disorder, and 2) we further
adjusted for variables associated (p<0.10) with either 5-
HTTLPR or hopelessness score.
Effect Modification. The effect of 5-HTTLPR on hopelessness was
modified by sex (p=0.04). We therefore stratified our analyses
according to patient sex, and race, based on an ap r i o r i
assumption of population stratification by race (though we
found no statistical evidence) of interaction between 5-HTTLPR
and race, p=0.63). Racial subgroups were first stratified by
“white” and “non-white”, in order to evaluate this association in
the largest, only adequately powered subgroup (white patients).
In a secondary analysis, we present the adjusted association
between the s allele and hopeless category in individual minority
(non-white) groups. Although underpowered, we intended to
evaluate for a trend in the effect of the s allele on hopelessness
across racial groups. We also present the results in only the male
subgroups as the assumption of proportional odds is violated in
females due to small sample size.
To assess for collinearity, we calculated a Spearman
correlation coefficient between Everson hopelessness and PHQ-
9 scores. The analyses were performed using STATA version 10
(STATA Corp, College Station, TX).
RESULTS
Patient Characteristics
Within the study cohort (n=870), 282 (32%) were homozygous
for the l allele (l/l genotype), 416 (48%) were heterozygous (l/s
genotype) and 172 (20%) were homozygous for the s allele (s/s
genotype). There were no differences in age, sex, antidepres-
sant use, medical illness, education, income, body mass index,
alcohol use, social support, and depressive symptoms ob-
served by genotype (Table 1). 5-HTTLPR genotype distribution
differedbyrace(Fig. 1)andwas consistentwith previousreports
in both this cohort
22 and other patient populations
41–43, where
African American patients had the lowest frequency of s allele
carriage. In contrast, Asians had the highest s allele frequen-
cy
16,17. Stratified racial groups were in accordance with Hardy-
Table 1. Characteristics of 870 Participants with Coronary Artery Disease According to 5-HTTLPR Genotype*
Patient Characteristics l/l N=282 (32%) l/s N=416 (48%) s/s N=172 (20%) p-value
Demographic characteristics
Age in Years, mean ± SD 66.7±11 66.9±11 66.5±11 0.89
Male 225 (80) 340 (82) 145 (84) 0.48
Self-Reported Race/Ethnicity <0.001
White 170 (60) 285 (69) 92 (53)
African American 79 (28) 37 (9) 12 (7)
Asian 10 (4) 39 (9) 37 (22)
Latino 17 (6) 41 (10) 22 (13)
Other 6 (2) 14 (3) 9 (5)
Married 119 (42) 175 (42) 73 (42) 0.99
High School Graduate 244 (87) 366 (88) 148 (86) 0.76
Median Income Category in $† 20-29,999 20-29,999 10-19,999 0.54
Medical History
Hypertension 209 (74) 286 (69) 117 (68) 0.21
Myocardial infarction 146 (52) 235 (57) 87 (51) 0.32
Stroke 34 (12) 60 (14) 29 (17) 0.35
Diabetes Mellitus§ 68 (24) 106 (25) 53 (31) 0.27
Medication Use
Antidepressant 53 (19) 84 (20) 30 (17) 0.73
Benzodiazepine or anxiolytic 34 (12) 53 (13) 13 (8) 0.19
Angiotensin receptor blocker 151 (54) 209 (50) 93 (54) 0.58
Beta-blocker 151 (54) 246 (59) 98 (57) 0.34
Other Characteristics
Body mass index, mean ± SD 28.7±6 28.1±5 28.6±5 0.37
Regular alcohol use 85 (30) 119 (29) 47 (27) 0.80
Current smoking 68 (24) 75 (18) 30 (17) 0.10
Presence of social support 194 (69) 269 (65) 115 (67) 0.51
Measures of Depression
Depressive Symptoms (PHQ-9 score), mean ± SD 5.2±5.3 5.2±5.4 5.1±5.7 0.97
Current Depression by CDIS-IV 55 (20) 102 (25%) 35 (20) 0.24
*All numbers given as N (%) except where otherwise indicated;†Out of a total of 865 patients (5 patients missing income data)
§ Out of a total of 869 patients (1 patient missing history of diabetes)
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sample (p=0.02), where homozygotes (both l/l and s/s) were
over-represented.
The 154 excluded patients were more likely to be Asian (21%
versus 10%) or African American (26% versus 15%), largely
due to increased frequency of rare 5-HTTLPR variants (15
Asians, 16 African Americans and 1 White patient), and less
likely to be White (44% versus 63%) or Latino (6% versus 9%),
but they did not differ according to other demographic or
clinical characteristics listed in Table 1 (data not shown).
5-HTTLPR and Hopelessness
Hopelessness was common in this sample, with 52% of
patients scoring as either moderate (N=333, 38%) or high (N=
119, 14%) hopelessness. The overall distribution of hopeless-
ness scores by genotype (Fig. 2) shows a proportionate increase
of s allele carriage in higher hopelessness categories (p value
trend=0.006) in the pooled sample. Hopeless category did not
vary according to sex, age or race (p>0.40). After adjustment for
self-reported race, mean hopelessness scores increased linearly
with the addition of each s allele (0.015, no evidence of
departure from trend, p=0.96), ranging from 2.5±0.1 among
patients with the l/l genotype to 3.1 ± 0.1 among patients with
the s/s genotype (Table 2). Results were strengthened after
further adjustment for age, antidepressant use, and depressive
symptoms (PHQ-9 score) (p=0.004). Results were unchanged (p
=0.002) after further adjustment for income, marital status,
high school graduation, smoking, social support and hyper-
tension (association between these covariates and genotype or
hopelessness p<0.10). Although we found significant Spear-
man correlation between PHQ-9 and Everson Hopelessness
scores (p<0.001), the coefficient of 0.38 was not concerning for
collinearity.
Effect Modification by Sex
We did not find differences in the effect of 5-HTTLPR genotype
on hopelessness by age (p-value for interaction=0.29), race (p=
0.63) antidepressant use (p=0.35), marital status (p=0.94),
social support (p=0.17), depressive symptoms (p=0.18) or
CDIS IV current depression (p=0.88). Adjusted results strati-
fied by sex (p value for interaction=0.04) demonstrated an
association between the 5-HTTLPR genotype and mean hope-
lessness score in males (p=0.001) but not in females (p=0.76)
(Table 2).
Findings in Non-Depressed Patients
Although we found no statistical evidence of interaction
between 5-HTTLPR genotype and current depression (p-value=
0.88), we excluded 192 patients with current major depressive
disorder as defined by CDIS-IV to evaluate the association
between5-HTTLPRgenotypeandhopelessnessinnon-depressed
patients. In the 678 nondepressed patients, we found a similar
trend of increasing mean hopelessness scores with each added s
allele (p=0.007 in the adjusted model) (Table 2). After stratifica-
tion by sex, we observed this effect only in the male sub-group.
5-HTTLPR and Hopeless Category
Using ordinal regression, we found that compared to patients
with l/l genotype in the pooled sample, adjusted (using
covariates of race, age, antidepressant use and depressive
symptoms) odds of higher hopeless category increased by 35%
for s/l genotype and 80% for s/s genotype (p-value for trend=
0.004) (Fig. 3). On analysis stratified by sex, we found that this
association was driven by its strong association only in the
larger male subgroup (Male: l/s OR 1.41, 95% CI 0.99-2.0; s/s
OR 2.23, 95% CI 1.5-3.4, p<0.001; Female: l/s OR 1.17, 95%
CI 0.57-2.4, s/s OR 0.66, 95% CI 0.24-1.8, p=0.42), where
males with s/s genotype were at 2.2-fold increased odds of
higher hopeless category compared to l/l males. After stratifi-
cation by “White” and “Non-white” racial groups, we found
statistically significant odds of higher hopeless category with
each increasing s allele in each of the male subgroups (White
male: l/s OR 1.24, 95% CI 0.81-1.9, s/s OR 2.32, 95% CI 1.3-
4.0, p=0.003; Non-white male: l/s OR 1.72, 95% CI 0.95-3.12,
s/s OR 2.18, 95% CI 1.1-4.2, p=0.02), but no effect in females
(p>0.40) (Fig. 3). There was no statistical evidence for interac-
Figure 1. Genotype frequency by self-reported race among 870
participants with coronary artery disease.
Figure 2. Hopeless category by genotype, where low=score ≤2,
moderate=score 3-5, and high=score ≥6 on the Everson hope-
lessness scale. The percentage of patients with low hopelessness
decreases with increased s allele carriage, whereas the percent-
age of patients with high hopelessness increases with s allele
carriage, p value for trend=0.006.
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=0.84). We stratified by individual minority groups (Fig. 4),
which demonstrated a similar trend of increased odds of
higher hopeless category associated with s allele carriage
across male racial subgroups in this sample.
DISCUSSION
In this cross-sectional study of 870 patients with stable
coronary artery disease, we found that the s allele of the 5-
HTT polymorphic region predicted higher propensity to hope-
lessness that persisted after controlling for age, depressive
symptoms, major depressive disorder, and antidepressant use.
Further, this association was present only in male patients,
where males with the s/s genotype had more than 2-fold
increased odds of a higher hopeless category than l/l males
across racial subgroups. We did not find any association
between 5-HTTLPR genotype and hopelessness in the female
sample in this study. Additionally, we did not find that the
effect between 5-HTTLPR genotype and hopelessness was
modified by race, depression (CDIS IV), depressive symptoms
(PHQ-9), antidepressant use, social support or age. After
excluding the 192 depressed patients, we saw a similar
association between 5-HTTLPR genotype and hopelessness.
Our findings suggest that hopelessness may be partly heritable
and that the serotonin (5-HT) system is likely to be involved.
Further, these results suggest that the s allele may increase
susceptibility to hopelessness in men with chronic cardiovas-
cular disease independent of depressive symptoms or major
depressive disorder.
Hopelessness is common in cardiovascular patients and
leads to increased cardiovascular morbidity and mortality
1.
This study demonstrates that there is a dose response
relationship between 5-HTTLPR s allele carriage and higher
hopelessness in men with chronic cardiovascular disease.
Across racial groups, the odds were more than doubled for a
higher hopeless category in men with the s/s genotype
compared to l/l genotype. The 2-item Everson Hopelessness
scale has been validated in cardiovascular patients, and
moderate and high hopelessness has been linked in a dose
response fashion with all-cause and cardiovascular-specific
mortality independent of depression
2. The findings of this
study illuminate underlying mechanisms for this important
and under-recognized phenotype.
Figure 3. Adjusted odds of higher hopeless category (low/moderate/high) in l/s (white diamonds) and s/s (black diamonds) genotype
compared to l/l referent among 870 patients with coronary disease.
Table 2. Mean Hopelessness Score by 5-HTTLPR Genotype
Model l/l l/s s/s p-value (trend)
All study participants (n=870) 282 (32%) 416 (48%) 171 (20%)
Adjusted by race 2.5±0.1 2.8±0.1 3.1±0.2 0.015
Adjusted by race, age, depressive symptoms and antidepressant use 2.5±0.1 2.8±0.1 3.1±0.1 0.004
Males (n=710) 2.5±0.1 2.9±0.1 3.3±0.2 0.001
Females (n=160) 2.4±0.3 2.6±0.2 2.2±0.4 0.76
Non-depressed participants (n=678) 227 (33%) 314 (46%) 137 (20%)
Adjusted by race 2.4±0.2 2.6±0.2 3.0±0.2 0.03
Adjusted by race, age, depressive symptoms, and antidepressant use 2.3±0.2 2.5±0.2 2.9±0.2 0.007
Males (n=579) 2.3±0.2 2.6±0.2 3.0±0.2 0.004
Females (n=99) 2.1±0.5 2.2±0.4 2.7±0.5 0.48
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The marked effect of 5-HTTLPR on measured hopelessness in
men but not in women is consistent with prior reports of sex-
specific genetic influences on serotonergic function
44. It has
been demonstrated that ovarian steroids stimulate expression
of the serotonin transporter
45,46, and the impact of a less
functional s allele may be moderated by an estrogen-induced
protective effect in women. Increased age has been associated
with decreased serotonergic function; however, the protective
effect of age related to 5-HTTLPR moderation antidepressant
response has only been found in patients under 25 years of
age
26. As our sample was older, it was not surprising that there
was no evidence of interaction between 5-HTTLPR and age.
Race Effects
Although we found no statistical evidence of interaction by
race, we accounted for the possibility that the allele frequency
differences between racial groups modified the relationship
between 5-HTTLPR and hopelessness by stratifying our anal-
ysis by race and adjusting for race in pooled analyses. This
addresses the concern of bias by population stratification,
where 5-HTTLPR variation between racial groups may be a
marker of different genetic and environmental factors leading
to hopelessness in each of these groups rather than the
etiology itself
41. Across races, we found a similar linear
association between 5-HTTLPR and hopelessness.
Genetics of Hopelessness
There has been very little research on the genetics of hope-
lessness. The only prior study by Gonda and colleagues
15 first
identified the association between the 5-HTTLPR s allele and
hopelessness as part of an evaluation of neuroticism traits in
healthy, young, white women. In comparison, we found an
association in older men with significant cardiovascular
disease, but no effect in the minority of women in the study.
Additionally, whereas our study used the Everson scale to
measure hopelessness, Gonda et al. used the Beck hopeless-
ness scale
47. Although correlation between these scoring
systems has not been evaluated, items on the scales are
similar.
The constructs of hopelessness and depression are difficult
to disentangle as hopelessness is often a fundamental charac-
teristic of depression. However, it has been proposed that
hopelessness may be a distinct phenotype from depression
and the independent association between the 5-HTTLPR
genotype and measured hopelessness in this sample supports
this hypothesis. Scales measuring hopelessness and depres-
sion differ: whereas depression scales focus on mood alter-
ation, hopelessness scales measure future orientation
6. Our
results suggest that pathophysiological differences may exist
between these two constructs as well. Is hopelessness really
just a marker of “sub-threshold” depression, one that is poorly
measured by traditional depression scales? Or is it a separate
entity often present in depression, but a functionally indepen-
dent construct? The independent association with 5-HTTLPR s
allele suggests that measured constructs of hopelessness and
depression are independent entities. Our results may also
provide new insights on the heterogeneity of results in the
evaluation of 5-HTTLPR and depression.
Strengths and Limitations
Our study is the largest to date to evaluate the association
between 5-HTTLPR polymorphism and hopelessness. However,
it is only powered to detect associations in the largest
subgroups (white race, male sex). Women were underrepre-
sented, and our current negative results do not rule out the
possibility of a type II error. Similarly, the association between
5-HTTLPR and hopelessness in males is a novel finding that
will have to be tested in other large samples. Further, results in
the Latino and African American groups are further limited by
possible population stratification, due to the racial admixture
present in these groups. However, the results in the non-white
groups serve to identify trends as the basis for more robust
future studies and meta-analyses. Lastly, it is not known
whether increased hopelessness associated with 5-HTTLPR s
allele is associated with meaningful clinical outcomes, such
as increased cardiovascular mortality or SSRI resistance.
Figure 4. Adjusted odds of higher hopeless category (low/moderate/high) in l/s (white diamonds) and s/s (black diamonds) genotype
compared to l/l referent according to self-reported race among 323 minority (non-white) patients with coronary disease.
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pressant use was not statistically significant, only 19% of
patients in our cohort were on any type of antidepressant, with
only half that number on SSRIs; therefore, our power to detect
the interaction in this cohort was small. Prior work by Otte et
al.
22 demonstrated an association between the 5-HTTLPR s
allele and increased norepinephrine secretion in Heart and
Soul. This finding along with other reports that the s allele
moderates cardiac reactivity
11 and increased cardiac events
mediated by depressive symptoms,
48 suggest that 5-HTTLPR
may play a larger role in cardiovascular health outcomes. Lastly,
although our sample included only highly educated adults with
cardiovascular disease, we suspect that the association between
5-HTTLPRandhopelessnessmaybesimilarinotherpopulations.
Despite these limitations we find an independent association
between the 5-HTTLPR s allele and significantly increased
hopelessness in men with cardiovascular disease.
In conclusion, we found that the 5-HTTLPR s allele was
associated with increased susceptibility to hopelessness in men
with cardiovascular disease, independent of depressive symp-
toms and major depressive disorder.
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